CA-VELODYNE-LIDAR
28.4.2020 14:02:06 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a three-year agreement with EasyMile, a global leader in driverless technology and smart vehicle solutions. EasyMile uses Velodyne lidar sensors in production of its EZ10 autonomous passenger shuttles that are deployed on public and private roads in more than 30 countries around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005241/en/
EasyMile will enhance its EZ10 shuttle fleet with Velodyne’s state-of-the-art sensors for safe and efficient navigation on roadways. Electric and driverless, the EZ10 shuttle was the one of the first autonomous shuttles launched in April 2015. It has a track record of over 200 deployments and more than 600,000 km driven in autonomous mode and one of the most advanced technology currently available. The shuttle, which has capacity for up to 15 passengers, includes a built-in automated electric ramp to support accessibility for individuals with disabilities.
“For precise navigation in real time, the EZ10s use our algorithm that fuses data from a variety of perception sensors, including lidar and camera, and localization sensors, including GPS, INS and odometry. Velodyne lidars along with radar scan for objects, vehicles, animals and people that might pose a collision threat, feeding that information to the vehicle’s control software,” explained Olivier Pairot, EasyMile’s Director of Product Marketing. “By utilizing Velodyne sensors, we are able to best gather information on every part of our environment, both close to the vehicle and at longer ranges.”
“Velodyne’s high performance lidar technology is a key component in enabling our autonomous vehicles to deliver smart mobility in urban, suburban and private environments,” said Benoit Perrin, Managing Director and COO, EasyMile. “Velodyne’s solutions have the reliability, quality and production scale we are looking for to continue to grow our fleet worldwide.”
“The EasyMile EZ10 provides a shared, inclusive driverless shuttle solution that improves public transport by connecting hubs and in many cases, delivers a transport service where there otherwise wasn’t one available,” said Erich Smidt, Executive Director Europe, Velodyne Lidar. “These shuttles show how Velodyne lidar sensors provide real-time perception data that enables safe and reliable operation for autonomous vehicles across business parks, public transport connections, university campuses and more.”
Velodyne’s sensors are optimized for outstanding indoor and outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, they can accurately detect a variety of objects.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About EasyMile
EasyMile is a global leader in driverless technology and smart vehicle solutions. The fast-growing company develops software to automate transportation platforms without the need for dedicated infrastructure. EasyMile’s cutting-edge technology is revolutionizing passenger and goods transportation, offering new mobility options. EasyMile has already deployed close to 250 driverless projects in more than 30 countries and transported people over 600,000 km. Clients include the world’s largest transport operators, city authorities, airports, corporations, business parks, and universities. Founded in 2014, EasyMile has a global presence with headquarters in Toulouse (France) and regional offices in Denver (USA), Berlin (Germany), Adelaide (Australia) and Singapore. The Company employs over 200 highly skilled and passionate employees specializing in robotics, computer vision and vehicle dynamics. Besides the two founders, CEO Gilbert Gagnaire and Board Member Philippe Ligier, EasyMile benefits from the backing of minority shareholders and strategic partners, Alstom, Continental and Bpifrance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
